CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net income/(loss)	$ (12,892)	$ 1,419
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation and amortization	13	15
Equity-based compensation expense	6,565	3,508
Amortization or accretion on marketable securities	946	229
Deferred income tax benefit	(19,568)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,140)	(4,352)
Accounts payable	3,137	(4,124)
Accrued expenses and other current liabilities	1,031	1,790
Net cash used in operating activities	(21,908)	(1,515)
Investing activities:
Purchase of marketable securities	(57,020)	(149,763)
Proceeds from sales and maturities of marketable securities	91,731	12,037
Net cash used in investing activities	34,711	(137,726)
Financing activities:
Proceeds from initial public offering	0	267,268
Payment of deferred offering costs	0	(2,688)
Proceeds from issuance of noncontrolling interests	1,153
Proceeds from issuance of convertible note	800
Proceeds from exercise of stock options	1,588
Net cash provided by financing activities	3,541	264,580
Net increase in cash and cash equivalents	16,344	125,339
Cash and cash equivalents at beginning of period	59,774	168,198
Cash and cash equivalents at end of period	76,118	293,537
Noncash financing activities
Deferred offering costs paid in the prior year	0	65
Tax withholding on stock awards not yet paid	$ 22